Cerebain Biotech Corp. (CBBT) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
600 ANTON BLVD. COSTA MESA, CA 92626 |
| State of Incorp. | NV |
| Fiscal Year End | June 30 |
| Industry (SIC) | 5047 - Medical, Dental, and Hospital Equipment and Supplies (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 3/31/2019 Q3 | 12/31/2018 Q2 | 9/30/2018 Q1 | 6/30/2018 Q4 | 3/31/2018 Q3 | 12/31/2017 Q2 | 9/30/2017 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 18 | 39 | 65 | 30 | 4 | 1 | |||
| Cash and cash equivalent | 18 | 39 | 65 | 30 | 4 | 1 | |||
| Prepaid expense | 14 | 21 | 27 | 95 | 64 | 138 | |||
| Total current assets: | 32 | 59 | 92 | 125 | 69 | 139 | |||
| Noncurrent Assets | |||||||||
| TOTAL ASSETS: | 32 | 59 | 92 | 125 | 69 | 139 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 1,416 | 1,288 | 1,453 | 1,261 | 1,211 | 1,183 | |||
| Taxes payable | 133 | 112 | 94 | 70 | 74 | 88 | |||
| Employee-related liabilities | 302 | 255 | 216 | 161 | 164 | 138 | |||
| Accounts payable | 981 | 921 | 1,143 | 1,030 | 973 | 957 | |||
| Debt | 3,521 | 538 | 468 | 384 | 360 | 93 | |||
| Due to related parties | 401 | 375 | 350 | 325 | 300 | 275 | |||
| Other undisclosed current liabilities | 987 | 979 | 834 | 781 | 364 | 364 | |||
| Total current liabilities: | 6,324 | 3,180 | 3,105 | 2,751 | 2,235 | 1,915 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 2,949 | 2,571 | 2,569 | 2,582 | 2,748 | ||||
| Long-term debt, excluding current maturities | 2,949 | 2,571 | 2,569 | 2,582 | 2,748 | ||||
| Total noncurrent liabilities: | 2,949 | 2,571 | 2,569 | 2,582 | 2,748 | ||||
| Total liabilities: | 6,324 | 6,129 | 5,675 | 5,320 | 4,817 | 4,663 | |||
| Equity | |||||||||
| Equity, attributable to parent | (6,292) | (6,070) | (5,584) | (5,195) | (4,748) | (4,524) | |||
| Preferred stock | |||||||||
| Common stock | 22 | 10 | 9 | 9 | 8 | 8 | |||
| Additional paid in capital | 27,044 | 26,907 | 26,857 | 26,826 | 26,618 | 23,430 | |||
| Accumulated deficit | (33,358) | (32,987) | (32,450) | (32,030) | (31,375) | (27,962) | |||
| Total equity: | (6,292) | (6,070) | (5,584) | (5,195) | (4,748) | (4,524) | |||
| TOTAL LIABILITIES AND EQUITY: | 32 | 59 | 92 | 125 | 69 | 139 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 3/31/2019 Q3 | 12/31/2018 Q2 | 9/30/2018 Q1 | 6/30/2018 Q4 | 3/31/2018 Q3 | 12/31/2017 Q2 | 9/30/2017 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 25 | 25 | 25 | 25 | ||||
| Gross profit: | 25 | 25 | 25 | 25 | ||||
| Operating expenses | (234) | (251) | (332) | (422) | (298) | (359) | ||
| Other undisclosed operating loss | (3,608) | |||||||
| Operating loss: | (234) | (251) | (3,915) | (397) | (273) | (334) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (137) | (286) | 3,420 | (233) | (3,115) | (72) | ||
| Interest and debt expense | (54) | (54) | 2,755 | (217) | (3,072) | 30 | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | (425) | (591) | 2,260 | (847) | (6,460) | (376) | ||
| Other undisclosed income from continuing operations before income taxes | 347 | |||||||
| Income (loss) from continuing operations: | (425) | (591) | 2,607 | (847) | (6,460) | (376) | ||
| Income (loss) before gain (loss) on sale of properties: | (425) | (591) | 2,607 | (847) | (6,460) | (376) | ||
| Net income (loss): | (425) | (591) | 2,607 | (847) | (6,460) | (376) | ||
| Other undisclosed net income (loss) attributable to parent | 54 | 54 | (3,027) | 192 | 3,047 | (55) | ||
| Net loss available to common stockholders, diluted: | (371) | (537) | (420) | (655) | (3,413) | (431) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 3/31/2019 Q3 | 12/31/2018 Q2 | 9/30/2018 Q1 | 6/30/2018 Q4 | 3/31/2018 Q3 | 12/31/2017 Q2 | 9/30/2017 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (425) | (591) | 2,607 | (847) | (6,460) | (376) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (425) | (591) | 2,607 | (847) | (6,460) | (376) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.